文献速递消化道肿瘤与早癌肝病

UNOS肝癌肝移植降期标准:25项研究的系统评价与Meta分析

UNOS Down-Staging Criteria for Liver Transplantation of Hepatocellular Carcinoma: Systematic Review and Meta-Analysis of 25 Studies.
PubMed 文献 · Clin Gastroenterol Hepatol · 2022-02-16

该系统评价与Meta分析检索了PubMed和EMBASE至2021年8月,纳入25项研究共3997例成人肝细胞癌(HCC)患者,评估降期成功率、肝移植率、HCC复发和总生存(OS)。采用UNOS降期(UNOS-DS)标准的研究中,意向性治疗(ITT)降期成功率为83.21%,肝移植率为48.61%,移植后HCC复发率为9.06%,均优于未采用或未明确UNOS-DS标准的研究。作者认为这些数据为UNOS-DS标准的应用提供了临床验证。

要点

  • UNOS-DS标准组ITT降期成功率为83.21%,非UNOS-DS或未明确标准组为45.93%(P < .001)。
  • UNOS-DS标准组ITT肝移植率为48.61%,非UNOS-DS或未明确标准组为28.60%(P = .030)。
  • UNOS-DS标准组移植后HCC复发率为9.06%,非UNOS-DS或未明确标准组为20.42%(P < .001)。

核心结论

  • 在遵循UNOS-DS标准的研究中,降期在五分之四的患者中成功,超过50%的患者接受了肝移植,移植后结局良好,这些数据为UNOS-DS标准的应用提供了临床验证。

研究设计与样本

  • 系统评价与Meta分析,检索PubMed和EMBASE数据库自建库至2021年8月,纳入25项研究共3997例成人HCC患者。
  • 采用重建个体参与者数据的汇总分析获得OS的稳健估计。

主要发现

  • UNOS-DS标准组与非UNOS-DS或未明确标准组相比,ITT降期成功率83.21% vs 45.93%(P < .001),ITT肝移植率48.61% vs 28.60%(P = .030),移植后HCC复发率9.06% vs 20.42%(P < .001)。
  • 采用UNOS-DS标准的研究中,自降期治疗开始计算的ITT 1年和5年OS分别为86%和58%,移植后1年和5年OS分别为94%和74%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Down-staging is commonly used to select patients with hepatocellular carcinoma (HCC) beyond Milan criteria (MC) for liver transplantation (LT), but outcomes are heterogenous. We aimed to estimate pooled down-staging success rates, HCC recurrence, and overall survival (OS), stratified by criteria used for baseline tumor burden. METHODS: We searched Pubmed and EMBASE databases from inception until August 2021 for studies reporting down-staging success (reduction of tumor burden to within MC) and outcomes of adult HCC patients. In addition, we performed a pooled analysis using reconstructed individual participant data to obtain robust estimates for OS. RESULTS: We screened 1059 articles and included 25 articles involving 3997 patients. Overall, 55.16% (45.49%-64.46%) underwent successful down-staging, and 31.52% (24.03%-40.11%) received LT (by intention-to-treat analysis [ITT]). Among patients who received LT, 16.01% (11.80%-21.37%) developed HCC recurrence. Comparing studies that used the United Network for Organ Sharing Down-Staging (UNOS-DS) criteria versus studies beyond UNOS-DS or did not specify criteria, down-staging success (by ITT) was 83.21% versus 45.93%, P < .001; the proportion who received LT (by ITT) was 48.61% vs 28.60%, P = .030; and HCC recurrence (among patients who received LT) occurred in 9.06% versus 20.42%, P < .001. Among studies that used UNOS-DS criteria, ITT 1- and 5-year OS from the initiation of down-staging treatment was 86% and 58%, respectively, whereas 1- and 5-year post-LT OS was 94% and 74%, respectively. CONCLUSIONS: Among studies that adhered to UNOS-DS criteria, down-staging was successful in four-fifths of patients, >50% received LT, and post-LT outcomes were excellent. These data provide clinical validation for the utilization of UNOS-DS criteria.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Tan DJH, Lim WH, Yong JN, et al. UNOS Down-Staging Criteria for Liver Transplantation of Hepatocellular Carcinoma: Systematic Review and Meta-Analysis of 25 Studies. Clin Gastroenterol Hepatol. 2022. PMID: 35181565. doi:10.1016/j.cgh.2022.02.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。